What is DMHA and how does it differ from DMAA?

DMHA (2-Aminoisoheptane, also called Octodrine) is a sympathomimetic amine that became popular in pre-workout supplements after the FDA banned DMAA in 2013. Like DMAA, DMHA releases norepinephrine and dopamine, producing stimulant and focus effects. However, DMHA is considered roughly 60–70% as potent as DMAA, with a slightly milder but still significant cardiovascular impact. Both compounds share a similar mechanism but differ in molecular structure and potency.

Has the FDA taken action against DMHA?

Yes. The FDA has issued multiple warning letters to supplement companies selling DMHA-containing products, declaring DMHA is not a lawful dietary ingredient. The FDA determined that DMHA does not meet the definition of a dietary ingredient under DSHEA, similar to its enforcement stance on DMAA. Products containing DMHA have been subject to recalls and market removal orders.

What are the main effects and risks of DMHA?

DMHA produces CNS stimulation, increased energy and focus, elevated blood pressure, and elevated heart rate. As a norepinephrine and dopamine releaser, it has effects lasting approximately 3–4 hours. Key risks include hypertension, tachycardia, anxiety, insomnia, and headache. Cardiovascular risk increases significantly when stacked with caffeine or other stimulants. Its safety profile is concerning enough that the FDA has flagged it as an unlawful ingredient.

Is DMHA legal to buy or sell?

In the United States, DMHA is not a lawful dietary supplement ingredient per FDA enforcement action, mirroring the regulatory status of DMAA. Supplement companies that sold DMHA-containing products have received FDA warning letters. While the compound itself is not a controlled substance, marketing it as a dietary supplement is considered illegal by the FDA. Many other countries similarly restrict or have not approved DMHA for use in food or supplements.

Stimulant • Oral • FDA Warning

DMHA: The DMAA Successor Under FDA Scrutiny

By MeetPeptide Research Team

Last updated: March 2026

DMHA (2-Aminoisoheptane / Octodrine) is a sympathomimetic amine that filled the void left by DMAA after its 2013 FDA ban. It releases norepinephrine and dopamine, producing stimulant and focus effects at 100–200mg doses. The FDA has issued warning letters to companies selling DMHA as a dietary supplement. This is a research-only reference.

Reported Oral Dose Range
In Supplement Products

Year DMAA Was Banned
— DMHA Emerged as Successor

FDA Warning Letters
Issued to Supplement Companies

Mechanism of Action

How DMHA Works as a Stimulant

DMHA is a structural relative of DMAA — a sympathomimetic amine that acts on the sympathetic nervous system through monoamine release and reuptake modulation. Weaker than DMAA but sharing the same core mechanism.

⚡

Sympathomimetic Mechanism

DMHA (2-Aminoisoheptane) is an indirect sympathomimetic — it enters presynaptic neurons via monoamine transporters and displaces stored catecholamines into the synapse. This results in elevated extracellular norepinephrine and dopamine without directly binding to adrenergic receptors. The mechanism is analogous to DMAA and structurally similar to amphetamine, though with lower intrinsic potency and a somewhat shorter duration of action.

🧠

Monoamine Release (NE / DA)

The primary pharmacological action of DMHA is releasing norepinephrine (NE) and, to a lesser degree, dopamine (DA) from nerve terminals. Elevated NE drives arousal, vigilance, blood pressure elevation, and vasoconstriction via alpha-adrenergic signaling. The dopamine component contributes to motivation and perceived energy. Users report a stimulant effect lasting 3–4 hours — shorter than DMAA's 8–11 hour half-life, which may reduce some residual cardiovascular burden.

⚖️

Comparison to DMAA — Weaker Potency

DMHA is estimated at roughly 60–70% of DMAA's potency on a milligram-for-milligram basis, which is why products typically used 100–200mg DMHA versus 25–75mg DMAA to achieve similar stimulant effects. The cardiovascular impact (BP elevation, HR increase) is present but less pronounced than DMAA at equivalent subjective doses. Despite the weaker profile, risks remain significant — especially when combined with caffeine, which dramatically amplifies adrenergic load.

🏛️

Regulatory Status

Following the DMAA enforcement actions, supplement companies pivoted to DMHA as a "legal" alternative. The FDA quickly identified DMHA in products and issued warning letters citing it as not a lawful dietary ingredient. Like DMAA, DMHA is not derived from a plant source as manufacturers sometimes claimed — it is a synthetic compound. The FDA's position is that DMHA does not meet DSHEA requirements, and its sale in dietary supplements is illegal in the United States.

Research Data

What the Data Shows

Available pharmacological data and regulatory enforcement metrics for DMHA, contextualized against DMAA benchmarks.

Potency vs DMAA (Relative Stimulant Strength)

Estimated mg-for-mg potency relative to DMAA at equivalent subjective effect

~60–70%

Blood Pressure Increase (Systolic)

Estimated BP elevation at typical 150mg dose based on sympathomimetic class data

+10–15 mmHg

Heart Rate Increase

Estimated HR elevation at typical dose — less than DMAA but still clinically relevant

+6–10 BPM

Focus / Energy Duration

Reported subjective duration of stimulant effects at standard doses

3–4 hours

FDA Enforcement Actions (Warning Letters)

Companies receiving FDA warning letters citing DMHA as unlawful dietary ingredient

12+

Safety Profile

DMHA Safety — A Concerning Picture

Hypertension Risk

Blood pressure elevation — especially dangerous in those with pre-existing hypertension

High

Tachycardia Risk

Elevated heart rate — compounded significantly when combined with caffeine

Moderate–High

Anxiety / Jitteriness

CNS overstimulation — especially at higher doses or in caffeine-sensitive individuals

Moderate

Insomnia Risk

Stimulant half-life may disrupt sleep if taken within 6 hours of bedtime

Moderate

Headache / Vasoconstriction

Peripheral vasoconstriction and adrenergic rebound on comedown

Common

Research Summary

Key Takeaways

📋 What the Research Shows

Sympathomimetic amine — releases NE and DA like DMAA, but ~60–70% as potent
100–200mg doses used in supplements to approximate DMAA stimulant effects
Duration shorter than DMAA — approximately 3–4 hours subjective effect window
Cardiovascular impact real — BP and HR elevation documented in sympathomimetic class
FDA has determined it is not a lawful dietary ingredient under DSHEA

🚫 Critical Legal & Safety Facts

FDA warning letters issued to 12+ supplement companies selling DMHA products
Not FDA-approved — not a lawful dietary ingredient in the United States
Stacking with caffeine dramatically amplifies cardiovascular risk
Pre-existing hypertension or cardiac conditions significantly increase risk profile
Marketed as "natural" but evidence of plant-derived origin is not credible

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.

Get the Guide →

⚠️ Important Disclaimer — FDA Warning Letters Issued

This page is for research and informational purposes only. DMHA (2-Aminoisoheptane / Octodrine) is NOT a lawful dietary supplement ingredient in the United States per FDA enforcement. The FDA has issued warning letters to supplement companies selling DMHA-containing products. MeetPeptide does not endorse, recommend, or encourage the use of DMHA. This content is provided solely to document the pharmacological and regulatory record of this compound. Consult a qualified physician before using any stimulant compound.